Sian Farrell

CEO at StimOxyGen

Presenter

Dr. Sian Farrell is CEO and co-founder of StimOxyGen Ltd, a UK-based preclinical oncology company developing oxygen-generating nanoparticle therapeutics to overcome tumour hypoxia. Her background spans pharmacy, nanomedicine, and translational oncology, with a focus on improving treatment response in aggressive solid tumours. Dr. Farrell completed her MPharm before pursuing doctoral research in nanoparticle-based therapeutic systems, where she worked extensively on oxygen-generating technologies and combination treatment strategies in pancreatic cancer models. She has led multiple translational research programs, securing competitive Innovate UK funding and advancing StimOxyGen’s lead asset toward IND-enabling development. Under her leadership, StimOxyGen has built a US-facing development strategy, including engagement with the FDA and collaboration with leading oncology centres in New York. Dr. Farrell’s focus is on positioning SGEN-33 as a platform technology to enhance radiotherapy and immunotherapy across hypoxic solid tumours.